ABVC Biopharma, Inc. entered into a definitive agreement with OncoX BioPharma, Inc. to grant them exclusive rights to develop and commercialize ABVC's BLEX 404 drug extract for the treatment of Myelodysplastic Syndrome, in exchange for a payment of $6,250,000 and royalties of 5% of Net Sales.